RU2003118584A - NEW PYRIDINE SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES - Google Patents

NEW PYRIDINE SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES

Info

Publication number
RU2003118584A
RU2003118584A RU2003118584/04A RU2003118584A RU2003118584A RU 2003118584 A RU2003118584 A RU 2003118584A RU 2003118584/04 A RU2003118584/04 A RU 2003118584/04A RU 2003118584 A RU2003118584 A RU 2003118584A RU 2003118584 A RU2003118584 A RU 2003118584A
Authority
RU
Russia
Prior art keywords
formula
compounds
compound
pyridinyl
treatment
Prior art date
Application number
RU2003118584/04A
Other languages
Russian (ru)
Inventor
Йоханнес-Петер ШТАШ (DE)
Йоханнес-Петер Шташ
Ахим ФОЙРЕР (DE)
Ахим Фойрер
Штефан ВАЙГАНД (DE)
Штефан Вайганд
Эльке ШТАЛЬ (DE)
Эльке ШТАЛЬ
Дитмар ФЛЮБАХЕР (DE)
Дитмар ФЛЮБАХЕР
Кристина АЛОНСО-АЛИГА (DE)
Кристина АЛОНСО-АЛИГА
Франк ВУНДЕР (DE)
Франк Вундер
Дитер ЛАНГ (DE)
Дитер Ланг
Клаус ДЕМБОВСКИ (US)
Клаус ДЕМБОВСКИ
Александер ШТРАУБ (DE)
Александер Штрауб
Элизабет ПЕРЦБОРН (DE)
Элизабет ПЕРЦБОРН
Original Assignee
Байер Акциенгезелльшафт (De)
Байер Акциенгезелльшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Акциенгезелльшафт (De), Байер Акциенгезелльшафт filed Critical Байер Акциенгезелльшафт (De)
Publication of RU2003118584A publication Critical patent/RU2003118584A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (16)

1. Соединения формулы (I)1. The compounds of formula (I)
Figure 00000001
Figure 00000001
в которойwherein R1 означает 4-пиридинил или 3-пиридинил,R 1 means 4-pyridinyl or 3-pyridinyl, R2 означает водород, NH2 или галоген,R 2 means hydrogen, NH 2 or halogen, а также соли, изомеры и гидраты этих соединений.as well as salts, isomers and hydrates of these compounds.
2. Соединения по п.1, в которых2. The compounds according to claim 1, in which R1 означает 4-пиридинил или 3-пиридинил,R 1 means 4-pyridinyl or 3-pyridinyl, R2 означает водород, NH2 или хлор,R 2 means hydrogen, NH 2 or chlorine, а также соли, изомеры и гидраты этих соединений.as well as salts, isomers and hydrates of these compounds. 3. Соединения по п.1, в которых3. The compounds according to claim 1, in which R1 означает 4-пиридинил или 3-пиридинил,R 1 means 4-pyridinyl or 3-pyridinyl, R2 означает водород,R 2 means hydrogen, а также соли, изомеры и гидраты этих соединений.as well as salts, isomers and hydrates of these compounds. 4. Способ получения соединения формулы (I), в котором соединение формулы (II)4. The method of obtaining the compounds of formula (I), in which the compound of formula (II)
Figure 00000002
Figure 00000002
подвергают взаимодействиюsubject to interaction А) с соединением формулы (III)A) with a compound of formula (III)
Figure 00000003
Figure 00000003
в которойwherein R1 такой, как указано выше,R 1 is as described above при необходимости, в органическом растворителе при нагревании с образованием соединения формулы (I),optionally in an organic solvent when heated to form a compound of formula (I), илиor В) с соединением формулы (IV)B) with a compound of formula (IV)
Figure 00000004
Figure 00000004
в которойwherein R1 такой, как указано выше,R 1 is as described above в органическом растворителе при нагревании с образованием соединения формулы (V)in an organic solvent when heated to form a compound of formula (V)
Figure 00000005
Figure 00000005
в которойwherein R1 такой, как указано выше,R 1 is as described above с последующим взаимодействием соединения формулы (V) с галогенирующим агентом с образованием соединения формулы (VI)followed by reaction of the compound of formula (V) with a halogenating agent to form a compound of formula (VI)
Figure 00000006
Figure 00000006
в которойwherein R1 такой, как указано выше,R 1 is as described above R2 означает галоген,R 2 means halogen, и дальнейшим взаимодействием соединения формулы (VI) с водным раствором аммиака при нагревании и повышенном давлении.and further reacting the compound of formula (VI) with an aqueous solution of ammonia under heating and elevated pressure.
5. Соединение формулы (I) для лечения болезней.5. The compound of formula (I) for the treatment of diseases. 6. Лекарственное средство, содержащее, по меньшей мере, одно соединение формулы (I) по п.1.6. A medicament containing at least one compound of formula (I) according to claim 1. 7. Способ получения лекарственного средства, отличающийся тем, что соединение формулы (I) по п.1, при необходимости, в сочетании с обычно используемыми вспомогательными веществами и добавками переводят в пригодную для приема форму.7. A method for producing a medicine, characterized in that the compound of formula (I) according to claim 1, if necessary, in combination with commonly used auxiliary substances and additives is converted into a suitable form for administration. 8. Лекарственное средство, содержащее соединение формулы (I) по п.1 в сочетании с органическими нитратами или донорами монооксида азота.8. A medicament containing a compound of formula (I) according to claim 1 in combination with organic nitrates or nitric oxide donors. 9. Лекарственное средство, содержащее соединение формулы (I) по п.1 в сочетании с соединениями, ингибирующими деструкцию циклического монофосфата гуанозина.9. A medicament containing a compound of formula (I) according to claim 1 in combination with compounds that inhibit the destruction of cyclic guanosine monophosphate. 10. Применение соединения формулы (I) по п.1 для получения лекарственных средств, предназначенных для лечения заболеваний кровообращения сердца.10. The use of the compounds of formula (I) according to claim 1 for the manufacture of drugs intended for the treatment of heart circulatory diseases. 11. Применение соединения формулы (I) по п.1 для получения лекарственных средств, предназначенных для лечения гипертонии.11. The use of the compounds of formula (I) according to claim 1 for the manufacture of medicines intended for the treatment of hypertension. 12. Применение соединения формулы (I) по п.1 для получения лекарственных средств, предназначенных для лечения тромбоэмболических заболеваний и ишемии.12. The use of the compounds of formula (I) according to claim 1 for the manufacture of drugs intended for the treatment of thromboembolic diseases and ischemia. 13. Применение соединения формулы (I) по п.1 для получения лекарственных средств, предназначенных для лечения сексуальной дисфункции.13. The use of the compounds of formula (I) according to claim 1 for the manufacture of drugs intended for the treatment of sexual dysfunction. 14. Применение соединения формулы (I) по п.1 для получения лекарственных средств, обладающих противовоспалительными свойствами.14. The use of the compounds of formula (I) according to claim 1 for the preparation of drugs having anti-inflammatory properties. 15. Применение соединения общей формулы (I) по п.1 для получения лекарственных средств, предназначенных для лечения заболеваний центральной нервной системы.15. The use of the compounds of General formula (I) according to claim 1 for the manufacture of drugs intended for the treatment of diseases of the central nervous system. 16. Применение по одному из п.п.8-13, причем соединение формулы (I) по п.1 используют в сочетании с органическими нитратами или донорами монооксида азота или в сочетании с соединениями, ингибирующими деструкцию циклического монофосфата гуанозина.16. The use according to one of claims 8 to 13, wherein the compound of formula (I) according to claim 1 is used in combination with organic nitrates or nitric oxide donors or in combination with compounds that inhibit the destruction of cyclic guanosine monophosphate.
RU2003118584/04A 2000-11-22 2001-11-09 NEW PYRIDINE SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES RU2003118584A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10057753.9 2000-11-22
DE10057753 2000-11-22
DE10131987A DE10131987A1 (en) 2000-11-22 2001-07-02 New pyridinyl-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
DE10131987.8 2001-07-02

Publications (1)

Publication Number Publication Date
RU2003118584A true RU2003118584A (en) 2004-12-20

Family

ID=7664122

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003118584/04A RU2003118584A (en) 2000-11-22 2001-11-09 NEW PYRIDINE SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES

Country Status (12)

Country Link
KR (1) KR20030065519A (en)
DE (2) DE10131987A1 (en)
DO (1) DOP2001000291A (en)
EC (1) ECSP034616A (en)
GT (1) GT200100235A (en)
HN (1) HN2001000261A (en)
MY (1) MY127212A (en)
PE (1) PE20020581A1 (en)
RU (1) RU2003118584A (en)
SV (1) SV2003000743A (en)
UA (1) UA74404C2 (en)
ZA (1) ZA200303887B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102485724B (en) * 2010-12-06 2015-08-12 中国人民解放军军事医学科学院毒物药物研究所 Substituted thiophene base pyrazolo-pyridines and medicinal use thereof
ES2864009T3 (en) 2011-11-25 2021-10-13 Adverio Pharma Gmbh 5-Fluoro-1H-pyrazolopyridines substituted in crystalline form
US10918639B2 (en) * 2016-10-11 2021-02-16 Bayer Pharma Aktiengesellschaft Combination containing SGC stimulators and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
GT200100235A (en) 2002-06-25
HN2001000261A (en) 2002-01-30
PE20020581A1 (en) 2002-07-13
KR20030065519A (en) 2003-08-06
DOP2001000291A (en) 2002-12-15
SV2003000743A (en) 2003-01-13
DE50106655D1 (en) 2005-08-04
UA74404C2 (en) 2005-12-15
MY127212A (en) 2006-11-30
DE10131987A1 (en) 2002-05-23
ZA200303887B (en) 2004-06-21
ECSP034616A (en) 2003-06-25

Similar Documents

Publication Publication Date Title
US3696197A (en) Pharmaceutical compositions containing homopyrimidazole derivatives
DE69032725T2 (en) CNS-active 8-heterocyclyl-2-aminotetralin derivatives
RU2324684C2 (en) Pyrimidine derivatives
CA2429312A1 (en) Novel pyridine-substituted pyrazolopyridine derivatives
RU2003118584A (en) NEW PYRIDINE SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES
DE2026997A1 (en)
CH618685A5 (en)
DE3233424A1 (en) ISOCHINOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE
DE2538424A1 (en) NEW OXAZOLIDINONE, METHOD OF PREPARATION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE2410938A1 (en) CHINAZOLINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THESE
DE1931240A1 (en) Aminoalkanecarboxylic acids
JPH0471067B2 (en)
DE2042504A1 (en) New derivatives of furan, thiophene and thiazole
US3459766A (en) 2,2,5,5-tetrakis(polyfluoromethyl)imidazolidines and their preparation
DE1925351A1 (en) Isopropylnorbornanamine
DE1250828B (en) Process for the preparation of the spasmolytically active 6,7,3 ', 4' - tetraethoxy-1-benzylidene-1,2,3,4 tetrahydroisoquinoline and its salts
TWI246422B (en) DNA-cleaving antitumor agents
CN115215760B (en) Aryl-containing quaternary ammonium salt derivative and application thereof in preparation of local anesthetic drugs
DE2428193C2 (en) p- (4-Quinolylamino) benzamides, processes for their preparation and pharmaceutical preparations containing the same
JPS63238019A (en) Antidepressant
DE1092476B (en) Process for the preparation of phenthiazine derivatives
JP2989059B2 (en) Substituted anilide
JPH0742287B2 (en) Hydrochloride of chloride of 2-aminoalkyl-9-hydroxy ellipticinium derivative and medicament containing the same
SU63474A1 (en) Antipellara drug
Kohl et al. Synthesis and central nervous system depressant activity of some 2-aryl-6-chloro-4-phenylquinazolines

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20071009